Curis, Inc. (CRIS:NASDAQ) closed at $0.386 on October 23, 2026, down 4.59% on the day. The stock trades 98.9% below its 52-week high of $33.60 and 17.1% above its 52-week low of $0.330. Over the past year, it lost 75.2%. Curis, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 251 trading sessions since October 22, 2025, CRIS closed higher on 72 days (29%). Its best day was June 26, 2026 (+52.38%) and its worst was June 25, 2026 (-38.24%). The stock moved 10% or more in a single session 24 times. It opened at least 5% above the previous day's high 1 time.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and p...
Find more stocks like CRIS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.